Detalhe da pesquisa
1.
Plasma fractalkine contributes to systemic myeloid diversity and PD-L1/PD-1 blockade in lung cancer.
EMBO Rep
; 24(8): e55884, 2023 08 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-37366231
2.
Oleuropein-driven reprogramming of the myeloid cell compartment to sensitise tumours to PD-1/PD-L1 blockade strategies.
Br J Cancer
; 130(5): 869-879, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-38195888
3.
PD-L1, a Master Regulator of Immunity 2.0.
Int J Mol Sci
; 24(5)2023 Feb 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-36901818
4.
mRNA Vaccines against SARS-CoV-2: Advantages and Caveats.
Int J Mol Sci
; 24(6)2023 Mar 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-36983017
5.
Leading Edge: Intratumor Delivery of Monoclonal Antibodies for the Treatment of Solid Tumors.
Int J Mol Sci
; 24(3)2023 Jan 31.
Artigo
em Inglês
| MEDLINE | ID: mdl-36768997
6.
Current Indications and Future Landscape of Bispecific Antibodies for the Treatment of Lung Cancer.
Int J Mol Sci
; 24(12)2023 Jun 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-37373003
7.
The multi-specific VH-based Humabody CB213 co-targets PD1 and LAG3 on T cells to promote anti-tumour activity.
Br J Cancer
; 126(8): 1168-1177, 2022 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-34969998
8.
Systemic CD4 Immunity and PD-L1/PD-1 Blockade Immunotherapy.
Int J Mol Sci
; 23(21)2022 Oct 31.
Artigo
em Inglês
| MEDLINE | ID: mdl-36362027
9.
How Can We Improve the Vaccination Response in Older People? Part II: Targeting Immunosenescence of Adaptive Immunity Cells.
Int J Mol Sci
; 23(17)2022 Aug 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-36077216
10.
How Can We Improve Vaccination Response in Old People? Part I: Targeting Immunosenescence of Innate Immunity Cells.
Int J Mol Sci
; 23(17)2022 Aug 31.
Artigo
em Inglês
| MEDLINE | ID: mdl-36077278
11.
Dual activity of PD-L1 targeted Doxorubicin immunoliposomes promoted an enhanced efficacy of the antitumor immune response in melanoma murine model.
J Nanobiotechnology
; 19(1): 102, 2021 Apr 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-33849551
12.
Understanding LAG-3 Signaling.
Int J Mol Sci
; 22(10)2021 May 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-34067904
13.
Hyperprogressive Disease: Main Features and Key Controversies.
Int J Mol Sci
; 22(7)2021 Apr 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-33916696
14.
Short-Term Local Expression of a PD-L1 Blocking Antibody from a Self-Replicating RNA Vector Induces Potent Antitumor Responses.
Mol Ther
; 27(11): 1892-1905, 2019 11 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-31563534
15.
PD-L1 in Systemic Immunity: Unraveling Its Contribution to PD-1/PD-L1 Blockade Immunotherapy.
Int J Mol Sci
; 21(16)2020 Aug 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-32824655
16.
Systemic Blood Immune Cell Populations as Biomarkers for the Outcome of Immune Checkpoint Inhibitor Therapies.
Int J Mol Sci
; 21(7)2020 Mar 31.
Artigo
em Inglês
| MEDLINE | ID: mdl-32244396
17.
PD-L1 Expression in Systemic Immune Cell Populations as a Potential Predictive Biomarker of Responses to PD-L1/PD-1 Blockade Therapy in Lung Cancer.
Int J Mol Sci
; 20(7)2019 Apr 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-30986912
18.
Radiopotentiation of enzalutamide over human prostate cancer cells as assessed by real-time cell monitoring.
Rep Pract Oncol Radiother
; 24(2): 221-226, 2019.
Artigo
em Inglês
| MEDLINE | ID: mdl-30858765
19.
Characterization of Macrophage Endogenous S-Nitrosoproteome Using a Cysteine-Specific Phosphonate Adaptable Tag in Combination with TiO2 Chromatography.
J Proteome Res
; 17(3): 1172-1182, 2018 03 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-29338241
20.
Drafting the proteome landscape of myeloid-derived suppressor cells.
Proteomics
; 16(2): 367-78, 2016 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-26403437